Stoke Therapeutics Quarterly Income Statement
NASDAQ: STOKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Stoke Therapeutics revenue and earnings
In the quarter ended Jun 30, 2026, Stoke Therapeutics generated $9.3 million in revenue, down 32.5% from the same quarter a year earlier. Stoke Therapeutics reported a net loss of $61.6 million, compared with a loss of $23.5 million a year earlier. Operating margin was -701.7%.
Diluted earnings per share came in at -$0.93.
Summary generated from market data by MetaCap's automated system. Methodology
Stoke Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.32M | 6.23M | 1.40M | 10.63M | 13.82M | 158.57M | 22.61M | 4.89M | 4.83M | 4.22M | 2.80M | 3.31M |
| Revenue growth (YoY) | -32.51% | -96.07% | -93.80% | +117.25% | +186.01% | +3661.12% | +707.07% | +47.94% | — | -18.17% | -14.26% | +13.87% |
| Operating Expenses | 74.75M | 59.65M | 62.84M | 53.72M | 41.12M | 47.33M | 36.27M | 34.90M | 34.17M | 32.59M | 32.39M | 30.54M |
| Research & Development | 49.50M | 39.67M | 41.70M | 37.70M | 25.86M | 32.68M | 23.42M | 22.20M | 21.14M | 22.37M | 21.78M | 20.27M |
| Selling, General & Admin | 25.25M | 19.97M | 21.15M | 16.03M | 15.26M | 14.65M | 12.84M | 12.69M | — | — | — | — |
| Operating Income | -65.43M | -53.42M | -61.44M | -43.09M | -27.30M | 111.24M | -13.65M | -30.00M | -29.34M | -28.37M | -29.59M | -27.23M |
| Interest Expense | 17.00K | 23.00K | 3.00K | 3.00K | 3.00K | 1.00K | -1.00K | 0 | 5.00K | 22.00K | — | — |
| Other Income (Expense) | 3.81M | 3.42M | 3.50M | 3.47M | 3.82M | 2.92M | 3.17M | 3.57M | 3.65M | 2.00M | 2.63M | 2.69M |
| Pretax Income | -61.62M | -50.00M | — | -39.63M | -23.48M | 114.16M | — | -26.43M | -25.70M | -26.37M | — | — |
| Income Tax | 0 | 0 | 0 | -1.28M | 0 | 1.28M | — | 0 | 0 | 0 | — | 0 |
| Net Income | -61.62M | -50.00M | -57.93M | -38.35M | -23.48M | 112.88M | -10.48M | -26.43M | -25.70M | -26.37M | -26.96M | -24.54M |
| Net Income growth (YoY) | — | -144.30% | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.93 | -0.79 | -1.02 | -0.65 | -0.40 | 1.95 | -0.15 | -0.47 | -0.46 | -0.57 | -0.61 | -0.55 |
| EPS (Diluted) | -0.93 | -0.79 | -0.97 | -0.65 | -0.40 | 1.90 | -0.15 | -0.47 | -0.46 | -0.57 | -0.61 | -0.55 |
| Shares Outstanding (Basic) | 66.02M | 63.06M | — | 58.61M | 58.35M | 57.86M | — | 56.34M | 55.77M | 46.25M | — | 44.27M |
| Shares Outstanding (Diluted) | 66.02M | 63.06M | — | 58.61M | 58.35M | 59.40M | — | 56.34M | 55.77M | 46.25M | — | 44.27M |
| EBITDA | -64.97M | -52.98M | -61.03M | -42.65M | -26.85M | 111.72M | -13.13M | -29.46M | -28.79M | -27.81M | -28.96M | -26.60M |
| Operating Margin | -701.65% | -857.57% | -4382.24% | -405.30% | -197.58% | 70.15% | -60.37% | -613.06% | -607.37% | -672.96% | -1055.89% | -823.28% |
| Net Margin | -660.78% | -802.75% | -4132.24% | -360.68% | -169.96% | 71.19% | -46.35% | -540.05% | -531.88% | -625.57% | -962.10% | -741.90% |
This table shows 12 quarterly periods of Stoke Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 17 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow STOK's reporting calendar. What is a income statement?